Blog

Keep up to date with the latest news from Instem.

CRODiscoveryIn Silico & Data InsightsIn Silico InsiderLeadscopeLeadscope Model ApplierPharmaceuticalPre-ClinicalPredictive ToxicologyToxicology

Advancing Risk-Based E&L Safety Assessment: The Role of ICH Q3E and Leadscope

Jignyasa Bal

As ICH Q3E advances a risk-based paradigm for E&L safety, the question is shifting from whether to assess risk toward how to do it consistently across a vast and diverse chemical space. Leadscope enables structure...

AgencyArtificial Intelligence and Machine LearningClimbCompany NewsCROPharmaceuticalPre-ClinicalProvantisRegulatory ComplianceRegulatory SubmissionsSENDSEND Advantage ServicesStudy ManagementSubmit

Instem Interact 2026 – A Resounding Success

Instem Team

Turning Insight into Innovation in Preclinical R&D

Regulatory ComplianceRegulatory SubmissionRegulatory SubmissionsSENDSensible SEND

What the FDA Webcast Revealed About SEND (and Why It Matters)

Marc Ellison

“For the first time, the FDA openly acknowledged that they are rejecting some SEND datasets because the quality isn’t good enough. No ambiguity. Just a clear statement that quality matters, and that poor SEND has...

Artificial Intelligence and Machine LearningBiotechClinicalClinicalClinical Trial AnalyticsCompany NewsCROData IntegrationPharmaceuticalPress ReleasesWorkflow Automation

d-wise Appoints 2x-CEO, ex-Labcorp Head of Software Solutions to Drive Next Phase of Strategy & Growth

Mike Thurogood, CMktr

BOSTON, USA – 21 April 2026: d-wise (an Instem company), a leader in statistical computing infrastructure and clinical trial transparency, today announced the appointment of Christine Oliver as its President. Christine brings over two decades...

Stay up to Date

Get expert tips, industry news, and fresh content delivered to your inbox.